The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
Dinnes
J
J
Wessex Institute for Health Research and Development, University of Southampton, Southampton, UK.
Cave
C
C
Huang
S
S
Major
K
K
Milne
R
R
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D003362:Cost-Benefit Analysis; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005910:Glioma / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D006801:Humans; D012008:Recurrence; D000077204:Temozolomide; D016896:Treatment Outcome; D006113:United Kingdom
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide